ArthroCare
This article was originally published in The Gray Sheet
Executive Summary
Proposed secondary offering of 1 mil. common stock shares is outlined in a registration statement filed with the Securities and Exchange Commission. Net proceeds will be used for further development and commercialization of products based on the firm's Coblation low-temperature tissue ablation technology, and for corporate and other general purposes. The Sunnyvale, California firm plans to pursue additional spinal applications within the next year (1"The Gray Sheet" Sept. 13, p. 12). Underwriters BancBoston Robertson Stephens and Bear Stearns have an overallotment option for an additional 150,000 shares
You may also be interested in...
ArthroCare's Entry Into Spine Surgery Market Attracts Backers To Stock
ArthroCare anticipates pursuing additional spinal applications within the next year for its Coblation-based surgical tools following the firm's recent entry into the European spine surgery market.
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.
Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune
The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.